GLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly?

55 After 4 weeks of treatment, obese mice receiving the nonapeptide showed a trend toward lower body weight (being around 10% lighter than controls) and weight gain was significantly reduced, to around 20% of that observed in control mice.

also in 53,322 other papers

Intraperitoneal glucose tolerance tests revealed no obvious differences between the groups, although there was a slight trend toward reduced glucose excursions in the GLP-1 nonapeptide-treated mice.

also in 4,078 other papers